Literature DB >> 31388824

Philadelphia-Negative Myeloproliferative Neoplasms: Laboratory Workup in the Era of Next-Generation Sequencing.

Zhuang Zuo1, Shaoying Li1, Jie Xu1, M James You1, Joseph D Khoury1, C Cameron Yin2.   

Abstract

PURPOSE OF REVIEW: To review the impact of next-generation sequencing (NGS) on laboratory approach of myeloproliferative neoplasms (MPNs). RECENT
FINDINGS: Next-generation sequencing has provided valuable information on the mutational landscape of MPNs and has been used for various applications, including diagnosis, risk stratification, monitoring of residual disease or disease progression, and target therapy. Most commonly, targeted sequencing of a panel of genes that have been shown to be recurrently mutated in myeloid neoplasms is used. Although numerous studies have shown the benefit of using NGS in the routine clinical care of MPN patients, the complexity of NGS data and how these data may contribute to the clinical outcome have limited the development of a standard clinical guideline. We review recent literature and discuss how to interpret and use NGS data in the clinical care of MPN patients.

Entities:  

Keywords:  Chronic neutrophilic leukemia; Essential thrombocythemia; Myeloproliferative neoplasms; Next-generation sequencing; Polycythemia vera; Primary myelofibrosis

Mesh:

Substances:

Year:  2019        PMID: 31388824     DOI: 10.1007/s11899-019-00534-8

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN: 1558-8211            Impact factor:   3.952


  80 in total

1.  EZH2 mutational status predicts poor survival in myelofibrosis.

Authors:  Paola Guglielmelli; Flavia Biamonte; Joannah Score; Claire Hidalgo-Curtis; Francisco Cervantes; Margherita Maffioli; Tiziana Fanelli; Thomas Ernst; Nils Winkelman; Amy V Jones; Katerina Zoi; Andreas Reiter; Andrew Duncombe; Laura Villani; Alberto Bosi; Giovanni Barosi; Nicholas C P Cross; Alessandro M Vannucchi
Journal:  Blood       Date:  2011-09-14       Impact factor: 22.113

2.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

3.  Targeted next-generation sequencing in blast phase myeloproliferative neoplasms.

Authors:  Terra L Lasho; Mythri Mudireddy; Christy M Finke; Curtis A Hanson; Rhett P Ketterling; Natasha Szuber; Kebede H Begna; Mrinal M Patnaik; Naseema Gangat; Animesh Pardanani; Ayalew Tefferi
Journal:  Blood Adv       Date:  2018-02-27

4.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

5.  Mutations and prognosis in primary myelofibrosis.

Authors:  A M Vannucchi; T L Lasho; P Guglielmelli; F Biamonte; A Pardanani; A Pereira; C Finke; J Score; N Gangat; C Mannarelli; R P Ketterling; G Rotunno; R A Knudson; M C Susini; R R Laborde; A Spolverini; A Pancrazzi; L Pieri; R Manfredini; E Tagliafico; R Zini; A Jones; K Zoi; A Reiter; A Duncombe; D Pietra; E Rumi; F Cervantes; G Barosi; M Cazzola; N C P Cross; A Tefferi
Journal:  Leukemia       Date:  2013-04-26       Impact factor: 11.528

6.  SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival.

Authors:  Terra L Lasho; Thitina Jimma; Christy M Finke; Mrinal Patnaik; Curtis A Hanson; Rhett P Ketterling; Animesh Pardanani; Ayalew Tefferi
Journal:  Blood       Date:  2012-09-11       Impact factor: 22.113

7.  Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.

Authors:  Francis H Grand; Claire E Hidalgo-Curtis; Thomas Ernst; Katerina Zoi; Christine Zoi; Carolann McGuire; Sebastian Kreil; Amy Jones; Joannah Score; Georgia Metzgeroth; David Oscier; Andrew Hall; Christian Brandts; Hubert Serve; Andreas Reiter; Andrew J Chase; Nicholas C P Cross
Journal:  Blood       Date:  2009-04-22       Impact factor: 22.113

8.  Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.

Authors:  Julia E Maxson; Jason Gotlib; Daniel A Pollyea; Angela G Fleischman; Anupriya Agarwal; Christopher A Eide; Daniel Bottomly; Beth Wilmot; Shannon K McWeeney; Cristina E Tognon; J Blake Pond; Robert H Collins; Basem Goueli; Stephen T Oh; Michael W Deininger; Bill H Chang; Marc M Loriaux; Brian J Druker; Jeffrey W Tyner
Journal:  N Engl J Med       Date:  2013-05-09       Impact factor: 91.245

9.  MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.

Authors:  Yana Pikman; Benjamin H Lee; Thomas Mercher; Elizabeth McDowell; Benjamin L Ebert; Maricel Gozo; Adam Cuker; Gerlinde Wernig; Sandra Moore; Ilene Galinsky; Daniel J DeAngelo; Jennifer J Clark; Stephanie J Lee; Todd R Golub; Martha Wadleigh; D Gary Gilliland; Ross L Levine
Journal:  PLoS Med       Date:  2006-07       Impact factor: 11.069

10.  MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia.

Authors:  M Haider; Y C Elala; N Gangat; C A Hanson; A Tefferi
Journal:  Blood Cancer J       Date:  2016-10-21       Impact factor: 11.037

View more
  1 in total

1.  Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signature.

Authors:  Samah Alimam; William Villiers; Richard Dillon; Michael Simpson; Manohursingh Runglall; Alexander Smith; Prodromos Chatzikyriakou; Paul Lavender; Anju Kanda; Ken Mills; Beatriz Bellosillo Paricio; James Kaufman-Cook; Sophie Ord; Shahram Kordasti; Deepti Radia; Claire Woodley; Yvonne Francis; Ghulam Mufti; Donal P McLornan; Claire N Harrison
Journal:  Blood Adv       Date:  2021-02-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.